Cessatech (CESSA) Q1 2026 earnings summary

Executive summary

• Advanced CT001, a nasal spray for pediatric acute pain, toward commercialization in the US and Europe, with regulatory reviews ongoing and manufacturing validation extending the US launch timeline.

• Presented positive clinical data for CT001 at a major pediatric pain medicine conference, strengthening scientific engagement.

• Expanded intellectual property portfolio with new patents in key markets.

Financial highlights

• Net revenue for Q1 2026 was DKK 0, compared to DKK 1,243,000 in Q1 2025, reflecting no new milestone payments.

• Operating loss was DKK -3,762,000, an improvement from DKK -5,610,000 in Q1 2025, due to lower development costs.

• Net loss for the period was DKK -3,228,000, compared to DKK -4,296,000 in Q1 2025.

• Cash at bank at period end was DKK 5,316,000.

• Earnings per share was DKK -0.17, compared to DKK -0.25 in Q1 2025.

Outlook and guidance

• US launch of CT001 delayed due to extended manufacturing validation and quality assurance; focus remains on completing these steps for market entry.

• EMA review of CT001 ongoing, with minimal clinical and CMC costs expected for the remainder of 2026 as development concludes.

• Cash position, supported by an extended DKK 10 million loan facility, is considered sufficient for the next 18–24 months.